Significant predictors of sustained remission over 3 years of adalimumab treatment
| Predictor, OR (95% CI) | Sustained ASDAS ID | Sustained PSpARC remission | ||
| Full model | Reduced model | Full model | Reduced model | |
| Baseline demographic and disease characteristics | ||||
| Normal hs-CRP (no vs yes) | NS | 0.18 (0.06 to 0.52) | NS | NS |
| Enthesitis | NS | NS | 0.79 (0.68 to 0.93) | 0.85 (0.77 to 0.95) |
| Prior DMARDs (yes vs no) | NS | NS | 0.20 (0.05 to 0.74) | 0.22 (0.07 to 0.66) |
| BASDAI | NS | 0.57 (0.41 to 0.78) | NS | 0.70 (0.50 to 0.97) |
| BMI | NS | NS | NS | 0.88 (0.77 to 0.99) |
| Treatment response (yes vs no) | ||||
| ASDAS MI at week 12 | 8.19 (1.08 to 61.91) | NS | NS | NS |
| ASDAS ID at week 12 | NS | 8.01 (2.47 to 25.97) | NS | NS |
| PSpARC remission at week 12 | NS | NS | 13.05 (1.75 to 97.52) | 20.27 (5.37 to 76.46) |
ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS ID, ASDAS inactive disease; ASDAS MI, ASDAS major improvement (Δ ≥2.0); BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; DMARD, disease-modifying antirheumatic drug; hs-CRP, high-sensitivity C-reactive protein; NS, not significant; PSpARC, Peripheral SpondyloArthritis Response Criteria.